No Data
No Data
LENZ Therapeutics Enters Into $30M Stock Purchase Agreement With Ridgeback Capital
Express News | Lenz Therapeutics Inc - to Use Pipe Funds for Lnz100 Launch Activities
Express News | Lenz Therapeutics Announces $30 Million Investment From Ridgeback Capital
Press Release: LENZ Therapeutics Announces $30 Million Investment From Ridgeback Capital
We Think LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Drive Business Growth
Piper Sandler Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $36
Piper Sandler analyst Joseph Catanzaro maintains $LENZ Therapeutics(LENZ.US)$ with a buy rating, and maintains the target price at $36.According to TipRanks data, the analyst has a success rate of 39.
No Data